drugset / Trial / NCT06633835
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
Non-randomizedParallel-groupOpen-labelPrevention
Summary
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
Timeline
- Start
- 2024-09-19
- Primary completion
- 2024-12-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Novavax COVID-19 vaccine | Vaccine | 0.5 ml | Intramuscular |
| Comparator | Pfizer mRNA COVID-19 vaccine | Vaccine | 0.3 ml | Intramuscular |